Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterol
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterol
Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterol is a phase 2 stage product being developed by Sumitomo Pharma for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT00685529. Target conditions include COPD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00685529 | Phase 2 | Completed |
Competing Products
20 competing products in COPD